

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**FORM 8-K**

---

**CURRENT REPORT**  
**Pursuant to Section 13 or 15(d)**  
**of the Securities Exchange Act of 1934**

October 3, 2017  
Date of Report (Date of earliest event reported)

---

**Adverum Biotechnologies, Inc.**

(Exact name of registrant as specified in its charter)

---

**Delaware**  
(State or other jurisdiction  
of incorporation)

**001-36579**  
(Commission  
File Number)

**20-5258327**  
(I.R.S. Employer  
Identification No.)

**1035 O'Brien Drive**  
**Menlo Park, CA 94025**  
(Address of principal executive offices, including zip code)

**(650) 272-6269**  
(Registrant's telephone number, including area code)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

---

---

**Item 5.02      Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On October 3, 2017, Steven D. Schwartz, M.D., a member of the Board of Directors of Adverum Biotechnologies, Inc., resigned as a director of Adverum, effective immediately. Dr. Schwartz has served as a member of Adverum's Board of Directors since September 2010 and is a co-founder of Adverum. His resignation is not the result of any disagreement with Adverum or any matter relating to its operations, practices or policies. Adverum is grateful to Dr. Schwartz for his leadership in the founding and development of the company.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**ADVERUM BIOTECHNOLOGIES, INC.**

Date: October 3, 2017

By: /s/ Leone Patterson  
Leone Patterson, Chief Financial Officer